Physician profile
Ather A Malik
NPI 1386616399
$2,938.88
in general payments reported to CMS, 2019-2025
34 companies · $506 in 2025
The $506 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $306 · 2021: $173 · 2022: $632 · 2023: $553 · 2024: $512 · 2025: $506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,571.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $298.64 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $290.18 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $252.90 | 2019-2023 | |
| Abbvie INC. | $195.91 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $194.25 | 2019-2025 | |
| Amgen INC. | $186.71 | 2019-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $182.82 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $168.05 | 2019-2025 | Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.17 | 2020-2025 | Jardiance, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $106.84 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $82.45 | 2022-2023 | Spravato |
| Checkpoint Surgical, INC | $68.97 | 2019 | |
| Exact Sciences Corporation | $65.25 | 2023-2024 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $60.63 | 2024 | Nexletol |
| Vanda Pharmaceuticals INC. | $56.89 | 2025 | Fanapt |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $54.36 | 2019-2022 | |
| Astellas Pharma US INC | $53.68 | 2023-2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.11 | 2021-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $46.62 | 2024-2025 | Voquezna |
| Xeris Pharmaceuticals, INC. | $43.13 | 2023 | Gvoke Hypopen |
| Radius Health, INC. | $35.71 | 2023-2024 | Tymlos |
| Lundbeck LLC | $35.69 | 2024 | Rexulti |
| Alkermes, INC. | $34.52 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $30.63 | 2019-2025 | Rexulti |
| Dynavax Technologies Corporation | $28.92 | 2022 | |
| Almatica Pharma LLC | $20.91 | 2025 | Loreev Xr |
| Phadia US INC. | $18.64 | 2022 | |
| Sanofi-Aventis U.S. LLC | $17.53 | 2021 | |
| Sanofi Pasteur INC. | $17.38 | 2020 | |
| Edwards Lifesciences Corporation | $16.23 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Antares Pharma, INC. | $15.93 | 2024 | Xyosted |
| Dexcom, INC. | $15.39 | 2023 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $14.72 | 2023 | Quviviq |
| Ibsa Pharma INC. | $14.12 | 2023 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ather Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.